Ichnos Glenmark presents data from Phase 1 study of ISB 2001 in multiple myeloma
In a presentation at the 66th American Society of Hematology Annual Meeting, Ichnos Glenmark Innovation (IGI) unveiled promising results from its Phase 1 clinical trial ... Read More
Adaptive Biotechnologies sees stock surge after clonoSEQ EU certification
In a major development for the biotechnology sector, Adaptive Biotechnologies Corporation witnessed a remarkable 29% surge in its stock value following a key regulatory milestone. ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma
GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in the treatment of relapsed or refractory multiple ... Read More
Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. ... Read More
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More
FDA greenlights Pfizer’s ELREXFIO for advanced multiple myeloma treatment
Pfizer Inc. has earned accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, ELREXFIO (elranatamab-bcmm). This drug aims to treat ... Read More
Aurobindo Pharma subsidiary receives FDA approval for Plerixafor Injection
Eugia Pharma Specialities Limited, a fully-owned subsidiary of India-based Aurobindo Pharma Limited, has received final approval from the US Food and Drug Administration (FDA). This ... Read More
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug conjugate (ADC) called LM-305 with AstraZeneca. LM-305 ... Read More